Financial Performance - Total revenue for Q1 2025 was $66.8 million, an increase from $59.5 million in Q1 2024[16] - Subscription revenue reached $32.2 million, while Amwell Medical Group visit revenue was $26.6 million[8] - Gross margin reported at 53%[8] - Net loss narrowed to $18.4 million compared to a net loss of $44.6 million in Q4 2024[8] - Adjusted EBITDA improved to a loss of $12.2 million from a loss of $22.8 million in Q4 2024[8] - Net loss for the three months ended March 31, 2025, was $18,356 thousand, a significant improvement from a net loss of $73,449 thousand in the same period of 2024, representing a reduction of approximately 75%[18] - Adjusted EBITDA for the three months ended March 31, 2025, was $(12,238) thousand, compared to $(45,651) thousand in the same period of 2024, indicating a 73% improvement year-over-year[24] Cash Flow and Liquidity - Cash flows from operating activities resulted in a net cash outflow of $25,108 thousand for Q1 2025, down from $59,756 thousand in Q1 2024, reflecting a 58% decrease in cash used[18] - Total cash, cash equivalents, and restricted cash at the end of Q1 2025 was $223,206 thousand, down from $309,394 thousand at the end of Q1 2024, a decrease of approximately 28%[18] - Cash paid for income taxes in Q1 2025 was $827 thousand, up from $630 thousand in Q1 2024, reflecting a 31% increase[18] Operational Metrics - Total visits for the quarter were 1.3 million, with projected AMG visits between 1.3 and 1.35 million[8] - The company reiterated its 2025 revenue guidance in the range of $250 to $260 million[8] - Q2 2025 revenue is expected to be between $62 million and $67 million, with adjusted EBITDA projected to be between ($12) million and ($10) million[8] Cost Management - Significant progress was made in revenue quality and cost alignment measures, targeting margin expansion for the year[3] - Stock-based compensation expense decreased to $7,339 thousand in Q1 2025 from $16,238 thousand in Q1 2024, a reduction of about 55%[18] - The company incurred $3,465 thousand in severance and strategic transformation costs in Q1 2025, compared to $8,659 thousand in Q1 2024, marking a 60% decrease[24] Revenue Recognition - Deferred revenue increased by $3,525 thousand in Q1 2025, compared to an increase of $14,589 thousand in Q1 2024, indicating a slowdown in revenue recognition[18] - The company reported a net gain on divestiture of $10,713 thousand in Q1 2025, which was not present in Q1 2024[18] - The company reported a decrease in accounts receivable by $6,120 thousand in Q1 2025, compared to a decrease of $27,506 thousand in Q1 2024, indicating a change in collection efficiency[18]

Core Insights - Amwell, a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, announced its financial results for the first quarter ended March 31, 2025 [1] Company Overview - Amwell offers a single, comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient, affordable, and effective care [3] - The platform includes software and services that support various clinical programs, providing unified, personalized access to diversified clinical programs across the care continuum [3] - Amwell has been operational for almost two decades, serving some of the largest healthcare organizations in the U.S. and worldwide, enabling care for millions of patients [3]

Company Overview - Amwell is a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, offering a unified care platform for payers and health systems [1] - The platform enhances patient access to convenient, affordable, and effective care, integrating various clinical programs [1] - Amwell has been operational for almost two decades, serving major healthcare organizations in the U.S. and globally [1] Upcoming Events - Mark Hirschhorn, CFO and COO of Amwell, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference on May 8 [4] - On June 24, Hirschhorn will also participate in the Truist Securities Healthcare Disruptors & Digital Health Conference in New York City [4]

Core Insights - Amwell will report its first quarter 2025 operating results on May 1, 2025, after stock market trading hours [1] - A live conference call and webcast will be held at 5 p.m. ET to discuss the operating results and provide a business update [1][2] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient and effective care [3] - The platform includes software and services that support various clinical programs, allowing for personalized access across the care continuum [3] - Amwell has been operational for nearly two decades, serving major healthcare organizations in the U.S. and globally [3]

Company Announcement - Amwell granted 220,844 restricted stock units (RSUs) to Dan Zamansky as an inducement for his employment as chief product and technology officer [1] - The RSUs will vest 25% on the six-month anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over four years [1] - If Zamansky's employment is terminated without cause or for good reason, a portion of the RSUs will vest based on the time he would have remained employed [1] Compensation Committee Approval - The RSU grant was approved by Amwell's Compensation Committee under the Inducement Plan and in accordance with NYSE's Listed Company Manual Rule 303A.08 [2] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to affordable and effective care [3] - The platform supports various clinical programs and aims to deliver integrated, future-ready solutions for millions of patients [3] - Amwell has been serving major healthcare organizations in the U.S. and globally for nearly two decades [3]

Core Insights - Amwell has appointed Dan Zamansky as the new chief product and technology officer, effective immediately, to enhance its technology-enabled care platform [1][2] - Zamansky's focus will be on improving access to convenient, affordable, and effective care through Amwell's comprehensive platform for payers and health systems [2][4] - He brings over a decade of experience from Amazon, where he led initiatives in product management and technology, including founding AWS Health AI [3][4] Company Overview - Amwell provides a single, comprehensive technology-enabled care platform that enhances patient access to diverse clinical programs [5] - The platform is designed to deliver integrated, future-ready solutions, operating at a large scale to serve millions of patients [5] - Amwell has been a key player in the healthcare sector for nearly two decades, partnering with some of the largest healthcare organizations in the U.S. and globally [5]

Core Points - Amwell granted RSUs covering 16,737 shares of its Class A common stock to four new employees as an inducement for their employment [1][2] - The RSUs will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over three years [1] - The grants were approved by the Compensation Committee under Amwell's Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08 [2] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to affordable and effective care [3] - The platform supports various clinical programs and offers integrated solutions for patients seeking care online, operating at a large scale to serve millions [3] - Amwell has been serving major healthcare organizations in the U.S. and globally for nearly two decades [3]

Company Overview - Amwell is a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, offering payers and health systems a unified care platform [2] - The platform enhances patient access to convenient, affordable, and effective care, integrating various clinical programs [2] - Amwell has been operational for almost two decades, serving major healthcare organizations in the U.S. and globally [2] Upcoming Events - Amwell will participate in the TD Cowen 24th Annual Health Care conference in Boston on March 4, 2025 [1] - Ido Schoenberg, M.D., the chairman and CEO of Amwell, will engage in a fireside chat at 9:10 a.m. ET, with an audio webcast available for investors [1]

American Well Corporation (NYSE:AMWL) Q4 2024 Earnings Conference Call February 12, 2025 5:00 PM ET Company Participants Sue Dooley - Head of Investor Relations Ido Schoenberg - Chairman & Chief Executive Officer Mark Hirschhorn - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Stan Berenshteyn - Wells Fargo Securities Jailendra Singh - Truist Securities Eric Percher - Nephron Research Charles Rhyee - TD Cowen Matt Shea - Needham & Company Kevin Caliendo - UBS David La ...

American Well Corporation (AMWL) reported $71.01 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 0.5%. EPS of -$2.77 for the same period compares to -$3.40 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $66.57 million, representing a surprise of +6.67%. The company delivered an EPS surprise of +1.77%, with the consensus EPS estimate being -$2.82.While investors closely watch year-over-year changes in headline numbers -- revenue a ...